BioMarker Strategies earns SBIR grant
This article was originally published in The Gray Sheet
Executive Summary
Firm is awarded a $254,000 Fast-Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute to develop its SnapPath live-tumor-cell testing system, designed to help oncologists determine the most effective course of drug treatment for their patients. The contract allows an additional $2 million in SBIR funding once the phase one work is complete, the company notes in an Oct. 7 press release